Bispecific Therapy
Bispecific antibody drugs are among the growing number of immunotherapies offering promising new options for treating certain types of cancer, including lymphomas that are often resistant to treatment. These drugs boost the action of the body’s immune system to find, target and kill cancer cells effectively.
This bispecific B-cell antigen-directed CD3 T-cell engager antibody drug therapy binds to multiple myeloma cells and activates T-cells to help the immune system recognize and destroy cancer.
Teclistamab (TECVAYLI®) Maintenance Therapy Program for Relapsed/Refractory Multiple Myeloma (RRMM)
Teclistamab (TECVAYLI®) is the first treatment of its kind approved by the U.S. Food and Drug Administration for relapsed/refractory multiple myeloma (RRMM).
Teclistamab has shown promising results for adults with RRMM whose cancer has come back or did not respond to prior treatment with at least four prior lines of therapy. In clinical research trials, 62 percent of patients had a favorable response to this therapy.
This bispecific antibody drug therapy, given as an injection, binds to proteins found on two types of cells — multiple myeloma cells and T-cells. This helps to enhance the immune system’s ability to destroy multiple myeloma cells throughout the body.
The therapy is administered on a stepped-up dosing schedule. There is a risk of unique side effects, including cytokine release syndrome, which can be life threatening. Initial treatments are typically administered in an inpatient hospital setting to monitor proper dosing and any adverse reactions. Patients can then proceed with ongoing maintenance on an outpatient basis with close monitoring, oversight and treatment guidance from skilled FCS clinicians.
The FCS Teclistamab Maintenance Therapy Program provides patients the opportunity to continue personalized treatment with skilled clinical professionals, with the added convenience of being close to home.
To learn more or request a referral to the program, email: SADBispecific@FLCancer.com.
